Mariko Nishikawa

Asahi, 5458585, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Timing and clinical burden of febrile neutropenia and treatment discontinuation during neoadjuvant chemotherapy.

Timing and clinical burden of febrile neutropenia and treatment discontinuation during neoadjuvant chemotherapy.

Journal: BMC cancer
Published: February 08, 2026

Clinical impact of the 21-gene recurrence score on adjuvant treatment selection in elderly patients with hormone receptor-positive, HER2-negative early breast cancer.

Clinical impact of the 21-gene recurrence score on adjuvant treatment selection in elderly patients with hormone receptor-positive, HER2-negative early breast cancer.

Journal: BMC cancer
Published: February 07, 2026

Pathological Complete Response after Robot-Assisted Pulmonary Resection Following CDK4/6 Inhibitor-Combined Endocrine Therapy for Endobronchial Oligometastatic Breast Cancer: A Case Report.

Pathological Complete Response after Robot-Assisted Pulmonary Resection Following CDK4/6 Inhibitor-Combined Endocrine Therapy for Endobronchial Oligometastatic Breast Cancer: A Case Report.

Journal: Surgical case reports
Published: January 28, 2026

Clinical-genomic risk discordance and its impact on treatment selection in premenopausal women with node-positive hormone receptor-positive breast cancer.

Clinical-genomic risk discordance and its impact on treatment selection in premenopausal women with node-positive hormone receptor-positive breast cancer.

Journal: BMC cancer
Published: January 23, 2026

BRCA Pathological Sequence Variants and Systemic and Local Tumor Immune Response in Breast Cancer

BRCA Pathological Sequence Variants and Systemic and Local Tumor Immune Response in Breast Cancer

Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 17, 2026

Clinical and imaging factors associated with prolonged ablation time in radiofrequency ablation for early-stage breast cancer.

Clinical and imaging factors associated with prolonged ablation time in radiofrequency ablation for early-stage breast cancer.

Journal: Breast cancer research and treatment
Published: January 03, 2026

Clinicopathological Significance of HER2 Expression Redefined by the HER2-low Concept in Ductal Carcinoma In Situ.

Clinicopathological Significance of HER2 Expression Redefined by the HER2-low Concept in Ductal Carcinoma In Situ.

Journal: Anticancer research
Published: October 05, 2025

Real-world Outcomes of Postoperative Management for Sentinel Lymph Node-positive Breast Cancer Without Intraoperative Assessment: A Single-institution Retrospective Study.

Real-world Outcomes of Postoperative Management for Sentinel Lymph Node-positive Breast Cancer Without Intraoperative Assessment: A Single-institution Retrospective Study.

Journal: Anticancer research
Published: October 03, 2025

Assessment of the Role of Neutrophil-Lymphocyte Ratio as a Prognostic Biomarker in Breast Cancer Patients: A Cross-sectional Study.

Assessment of the Role of Neutrophil-Lymphocyte Ratio as a Prognostic Biomarker in Breast Cancer Patients: A Cross-sectional Study.

Journal: Cancer diagnosis & prognosis
Published: October 02, 2025

Clinical-Genomic Risk Discordance in Early HR+/HER2- Breast Cancer: A Real-World Cohort from Japan Demonstrates Treatment Impact of Oncotype DX.

Clinical-Genomic Risk Discordance in Early HR+/HER2- Breast Cancer: A Real-World Cohort from Japan Demonstrates Treatment Impact of Oncotype DX.

Journal: Anticancer research
Published: September 30, 2025

Efficacy and Safety of Subcutaneous Pertuzumab-Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan.

Efficacy and Safety of Subcutaneous Pertuzumab-Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan.

Journal: Anticancer research
Published: September 18, 2025

Radiological Complete Response as a Prognostic Marker in HR-positive Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: Implications for Treatment De-escalation.

Radiological Complete Response as a Prognostic Marker in HR-positive Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: Implications for Treatment De-escalation.

Journal: Anticancer research
Published: September 14, 2025
Showing 1-12 of 20

Last Updated: 09/26/2026